文献速递头颈部肿瘤放疗

再程放疗对比全身治疗用于局部区域复发头颈癌的管理

Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer.
PubMed 文献 · Radiother Oncol · 2024-04-16

本机构登记研究纳入65例不可手术的局部区域复发头颈鳞癌患者,40例(62%)选择再程放疗,25例(38%)仅接受初始全身治疗。再程放疗较全身治疗改善了2年总生存(32% vs 11%)、无进展生存(31% vs 7%)和局部区域控制(39% vs 3%)(两者p<0.05),但3级及以上毒性发生率更高(53% vs 28%,p<0.001),且3例治疗相关死亡均发生于再程放疗组。

要点

  • 再程放疗组2年总生存32% vs 全身治疗组11%,无进展生存31% vs 7%,局部区域控制39% vs 3%(两者p<0.05)。
  • 再程放疗组任何新发3级及以上毒性发生率为53% vs 全身治疗组28%(p<0.001)。
  • 3例治疗相关死亡均发生于再程放疗组;3级及以上晚期毒性再程放疗组48% vs 全身治疗组12%(p<0.001)。

核心结论

  • 对于适当选择的局部区域复发头颈癌患者,再程放疗较全身治疗改善了总生存,但必须考虑相对较高的毒性风险。

研究设计与样本

  • 本机构登记资料回顾性识别65例不适合手术的局部区域复发头颈鳞状细胞癌患者,40例(62%)选择再程放疗,25例(38%)仅接受初始全身治疗。

主要发现

  • 再程放疗组 vs 全身治疗组:2年总生存32% vs 11%,无进展生存31% vs 7%,局部区域控制39% vs 3%(两者p<0.05)。
  • 再程放疗组 vs 全身治疗组:任何新发3级及以上毒性发生率53% vs 28%(p<0.001)。
  • 3级及以上晚期毒性发生率再程放疗组48% vs 全身治疗组12%(p<0.001)。
  • 共3例治疗相关死亡,全部发生于再程放疗组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The optimal management of local-regionally recurrent head and neck cancer that is not amenable to surgical resection is uncertain. We sought to compare outcomes among patients treated with and without re-irradiation in this setting. METHODS AND MATERIALS: A review of institutional registries identified 65 patients with local-regionally recurrent squamous cell carcinoma of the head and neck who were ineligible for surgery. Forty patients (62 %) opted for re-irradiation with the remaining 25 patients (38 %) undergoing initial systemic therapy alone. All patients had measurable disease. Forty-three patients (66 %) were male and twenty-two (33 %) were female. The median age at the time of recurrence was 59 years (range, 39-84 years). The most common primary sites of disease were the oropharynx, (n = 25), oral cavity (N = 19), and nasopharynx (n = 11). The median interval from completion of prior radiation to the diagnosis of recurrent disease was 35 months (range, 2-102 months). RESULTS: Re-irradiation improved 2-year overall survival, (32 % versus 11 %), progression-free survival (31 % versus 7 %), and local-regional control (39 % versus 3 %) compared to systemic therapy alone (p < 0.05, for both). The likelihood of developing any new grade 3+ toxicity was significantly higher among patients treated by re-irradiation compared to those treated by systemic therapy (53 % vs. 28 %, p < 0.001). There were 3 treatment-related fatalities, all of which occurred in the re-irradiation group. The incidence of grade 3+ late toxicity was 48 % and 12 % for patients in the re-irradiation and systemic therapy cohorts, respectively (p < 0.001). CONCLUSION: Although re-irradiation improved overall survival compared to systemic therapy for appropriately selected patients with local-regionally recurrent head and neck cancer, the relatively high risk of toxicity must be considered.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Chen AM, Harris JP, Nabar R, et al. Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer. Radiother Oncol. 2024. PMID: 38636710. doi:10.1016/j.radonc.2024.110278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。